To summarize, because of the known physiological actions of CGRP and signals in adverse effect reporting systems and/or case reports, and chiefly as a precautionary principle, anti-CGRP/rec mAbs are contraindicated in subjects with recent stroke, unstable angina, myocardial infarction or severe Raynaud’s phenomenon. This evidence concerns the gene CALCA and angina unstable.